Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 67Sarcoma 4Other neoplasm 3Endocrine 3NET 2CNS 2Tumor-Agnostic 1Thoracic 1

Conditions

Rectal Neuroendocrine Tumors 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Endoscopic Mucosal Resection × NET × Clear all
NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase NA Not yet recruiting
118 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

NCT06121752 2024-10-15

DNET

Asian Institute of Gastroenterology, India

Phase NA Unknown
54 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡